INTENSITY THERAPEUTICS, INC. (INTS): Nasdaq/NYSE listing notice — Intensity Therapeutics receives Nasdaq extension until June 1, 2026 to meet $1 bid price rule

INTENSITY THERAPEUTICS, INC.

Received 180-day extension from Nasdaq to June 1, 2026 to regain compliance with $1.00 minimum bid price rule.
Initial compliance period ended Dec 3, 2025; company previously notified of deficiency on June 6, 2025.
To regain compliance, closing bid price must be at least $1.00 for ten consecutive business days before June 1, 2026.
Company considering reverse stock split if needed; trading symbol INTS continues on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

INTENSITY THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 4, 2025, the “Company received a second letter (the “December 2025 Nasdaq Letter”) from Nasdaq stating that the Company is eligible for an additional 180 calendar days, or until June 1, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Staff of the Nasdaq (the “Staff”) determined that the Company is eligible for the second 180 calendar day period, or until June 1, 2026, to regain compliance with the Rule based on the Staff’s determination that the Company must continue to meet the continued listing requirement

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-25-000111

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.